Jul 19, 2018

Bioxodes will present up-to-date preclinical data during the annual ISTH SSC meeting on Thursday 19 July 2018 in Dublin.

Poster presentations:

Abstract presentation number: PB503 - "Ir-CPI: an original inhibitor of thrombosis and thrombosis-associated with cancer"

Abstract presentation number: PB407 - "Ir-CPI, a contact phase inhibitor, provides an effective and safe thromboprotection during extracorporeal circulation with open-heart surgery"

Poster Session #2, Liffey B

19.07.2018

Oral presentation:

"Ir-CPI a New Potent Inhibitor of Thrombosis and Thrombosis Associated with Cancer"

SSC Session, Wicklow Hall 2

19.07.2018, 10:30 - 12:30

Link: http://www.ssc2018.org/

Dublin, Ireland

Jul 12, 2017

Bioxodes to present preclinical data for its main product, Ir-CPI, at ISTH 2017 annual congress.

Abstract Title: "Efficacy of a Novel Contact Pathway Inhibitor, Ir-CPI, on in vitro Clotting Induced by PCI Catheter Segment"

Link: http://www.isth2017.org/

Berlin, Germany

May 1, 2016

Bioxodes to participate at the ISTH SCC 2016 annual congress.

Montpellier, France

Jun 1, 2015

Bioxodes to present preclinical data for its main product, Ir-CPI, at ISTH 2015 annual congress.

Abstract titles : 
“Efficacy of a novel contact pathway inhibitor, Ir-CPI, in an extracorporeal membrane oxygenator model”
“Antithrombotic effects of Ir-CPI in an arterio-venous shunt model in the rabbit”
“Evaluation of the effects of a novel contact pathway inhibitor, Ir-CPI, on in vitro platelet function and coagulation”

Toronto, Canada